Skip to content

Cohort study: The effect of exercise during neoadjuvant chemotherapy on the short-term efficacy and prognosis of advanced gastric cancer

Cohort study: The effect of exercise during neoadjuvant chemotherapy on the short-term efficacy and prognosis of advanced gastric cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114458
Enrollment
Unknown
Registered
2025-12-12
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Stable exercise group :None
Inactive group:None

Sponsors

The First Hospital of Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old; 2. Gastric malignancy confirmed by histology or cytology; 3. no contraindication to chemotherapy, receiving neoadjuvant chemotherapy, and having a clear intention of radical surgery; 4.ECOG score 0-1, Karnofsky score >= 70, or ability to complete a physical function test such as 6-minute Walk Test > 400 meters; 5. Conscious, no communication disorder, able to understand the research content and complete motor commands; 6. Volunteer to participate in this study and have signed written informed consent.

Exclusion criteria

Exclusion criteria: 1. Distant metastasis (stage IV); 2. other antineoplastic therapy before NAC or preoperative preparation; 3. Plan for non-radical surgery; 4. combined with other malignant tumors; 5. Acute or chronic diseases judged by the attending physician to be unsuitable for exercise, such as severe arthritis, neurological diseases, heart failure NYHA class III-IV, uncontrolled severe respiratory diseases, etc. 6. Severe, uncontrolled pain (NRS >=7) caused by the tumor itself or the treatment; 7. Any history of mental illness, poor compliance, and inability to understand and cooperate with the study protocol; 8. Participate in other interventional clinical studies that may interfere with the outcomes of the study.

Design outcomes

Primary

MeasureTime frame
Number of exercise steps;

Secondary

MeasureTime frame
Chemotherapy tolerance: Incidence and severity of myelosuppression (neutropenia, thrombocytopenia, anemia);Chemotherapy efficacy: Tumor response classification and clinical downstaging rate;Postoperative outcomes: Operative time, intraoperative blood loss, number of lymph nodes dissected, incidence and severity of postoperative complications (Clavien-Dindo classification), duration of drainage tube placement, time to first flatus, time to initiation of liquid diet, and length of postoperative hospital stay;Long-term prognosis: Overall survival;

Countries

China

Contacts

Public ContactYuan Wenzhen

The First Hospital of Lanzhou University

yuanwzh@lzu.edu.cn+86 138 9338 2066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026